← All Viridian Therapeutics, Inc\de filings

Viridian Therapeutics, Inc\de DEF 14A proxy statements

Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.

NASDAQ
VRDN
Viridian Therapeutics, Inc\de
DEF: Viridian Therapeutics 2026 Proxy Statement Overview
Viridian Therapeutics has issued its 2026 proxy statement detailing director elections, auditor ratification, and executive compensation advisory votes.
NASDAQ
VRDN
Viridian Therapeutics, Inc\de
DEFA14A: Viridian Therapeutics Sets Date for 2025 Annual Meeting, Outlines Key Proposals for Stockholder Vote
Viridian Therapeutics has scheduled its 2025 Annual Meeting for June 20, 2025, and is seeking stockholder votes on director elections, auditor ratification, executive compensation, an equity incentive plan amendment, and an employee stock purchase plan.
NASDAQ
VRDN
Viridian Therapeutics, Inc\de
DEF: Viridian Therapeutics Seeks Stockholder Approval for Amended Equity Incentive Plan and New Employee Stock Purchase Plan
Viridian Therapeutics is asking stockholders to approve an amended equity incentive plan with an increased share pool and a new employee stock purchase plan at the upcoming annual meeting.
NASDAQ
VRDN
Viridian Therapeutics, Inc\de
DEFA14A: Viridian Therapeutics Seeks Stockholder Approval for Equity Incentive Plan Increase to Attract and Retain Talent
Viridian Therapeutics is urging stockholders to approve an increase in shares available under its equity incentive plan to maintain competitiveness in the biotech talent market and support company growth.
NASDAQ
VRDN
Viridian Therapeutics, Inc\de
DEFA14A: Viridian Therapeutics Sets Date for Annual Stockholder Meeting, Outlines Key Proposals
Viridian Therapeutics will hold its annual stockholder meeting on June 17, 2024, with proposals including the election of directors, ratification of the auditor, executive compensation approval, and an amendment to the equity incentive plan.
NASDAQ
VRDN
Viridian Therapeutics, Inc\de
DEF 14A: Viridian Therapeutics Seeks Stockholder Approval for Director Elections, Auditor Ratification, Executive Compensation, and Equity Incentive Plan Amendment
Viridian Therapeutics is holding its 2024 Annual Meeting of Stockholders on June 17, 2024, to vote on key proposals including director elections, auditor ratification, executive compensation, and an amendment to the equity incentive plan.